Janine Kutzsche

Janine Kutzsche

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2014 in Journal of Cell Biology
Verified
Journal Article
Open access
ARAlexander Rouvinski
Alexander Rouvinski
SKSharon Karniely
Sharon Karniely
MKMaria Kounin
Maria Kounin
SMSanaa Moussa
Sanaa Moussa
MGMiri D. Goldberg
Miri D. Goldberg
ATAlbert Taraboulos
Albert Taraboulos
Mammalian prions refold host glycosylphosphatidylinositol-anchored PrPC into β-sheet–rich PrPSc. PrPSc is rapidly truncated into a C-terminal PrP27-30 core that is stable for days in endolysosomes. The nature of cell-associated prions, their attachment to membranes and rafts, and their subcellular locations are poorly understood; live prion visualization has not previously been achieved. A key obstacle has been the inaccessibility of PrP27-30 epitopes. We overcame this hurdle by focusing on nascent full-length PrPSc rather than on its truncated PrP27-30 product. We show that N-terminal PrPSc epitopes are exposed in their physiological context and visualize, for the first time, PrPSc in living cells. PrPSc resides for hours in unexpected cell-surface, slow moving strings and webs, sheltered from endocytosis. Prion strings observed by light and scanning electron microscopy were thin, micrometer-long structures. They were firmly cell associated, resisted phosphatidylinositol-specific phospholipase C, aligned with raft markers, fluoresced with thioflavin, and were rapidly abolished by anti-prion glycans. Prion strings and webs are the first demonstration of membrane-anchored PrPSc amyloids.

23 September 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
OBOleksandr Brener
Oleksandr Brener
TDTina Dunkelmann
Tina Dunkelmann
LGLothar Gremer
Lothar Gremer
TGThomas van Groen
Thomas van Groen
EMEwa A. Mirecka
Ewa A. Mirecka
DWDieter Willbold
Dieter Willbold
Strong evidence exists for a central role of amyloid β-protein (Aβ) oligomers in the pathogenesis of Alzheimer’s disease. We have developed a fast, reliable and robust in vitro assay, termed QIAD, to quantify the effect of any compound on the Aβ aggregate size distribution. Applying QIAD, we studied the effect of homotaurine, scyllo-inositol, EGCG, the benzofuran derivative KMS88009, ZAβ3W, the D-enantiomeric peptide D3 and its tandem version D3D3 on Aβ aggregation. The predictive power of the assay for in vivo efficacy is demonstrated by comparing the oligomer elimination efficiency of D3 and D3D3 with their treatment effects in animal models of Alzheimer´s disease.

24 November 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TGThomas Van Groen
Thomas Van Groen
SSSarah Schemmert
Sarah Schemmert
OBOleksandr Brener
Oleksandr Brener
LGLothar Gremer
Lothar Gremer
TZTamar Ziehm
Tamar Ziehm
DWDieter Willbold
Dieter Willbold
While amyloid-β protein (Aβ) aggregation into insoluble plaques is one of the pathological hallmarks of Alzheimer’s disease (AD), soluble oligomeric Aβ has been hypothesized to be responsible for synapse damage, neurodegeneration, learning, and memory deficits in AD. Here, we investigate the in vitro and in vivo efficacy of the d-enantiomeric peptide RD2, a rationally designed derivative of the previously described lead compound D3, which has been developed to efficiently eliminate toxic Aβ42 oligomers as a promising treatment strategy for AD. Besides the detailed in vitro characterization of RD2, we also report the results of a treatment study of APP/PS1 mice with RD2. After 28 days of treatment we observed enhancement of cognition and learning behaviour. Analysis on brain plaque load did not reveal significant changes, but a significant reduction of insoluble Aβ42. Our findings demonstrate that RD2 was significantly more efficient in Aβ oligomer elimination in vitro compared to D3. Enhanced cognition without reduction of plaque pathology in parallel suggests that synaptic malfunction due to Aβ oligomers rather than plaque pathology is decisive for disease development and progression. Thus, Aβ oligomer elimination by RD2 treatment may be also beneficial for AD patients.

1 January 2020 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Verified
Journal Article
Open access
PDF file
JKJanine Kutzsche
Janine Kutzsche
DJDagmar Jürgens
Dagmar Jürgens
AWAntje Willuweit
Antje Willuweit
KAKnut Adermann
Knut Adermann
CFCarola Fuchs
Carola Fuchs
DWDieter Willbold
Dieter Willbold
Introduction: PRI‐002 is an orally available anti–amyloid beta (Aβ) prionic compound developed for direct disassembly of toxic Aβ oligomers relevant to Alzheimer's disease. Methods: Two placebo‐controlled clinical phase I trials with oral dosing of PRI‐002 were conducted in healthy young subjects: A single ascending dose trial (4, 12, 36, 108, or 320 mg PRI‐002 or placebo) in 40 participants followed by a multiple ascending dose study with daily 160 mg PRI‐002 for 14 days or 320 mg for 28 days in 24 participants. The main objectives were safety, tolerability, and evaluation of pharmacokinetic (PK) parameters. Results: PRI‐002 was safe and well tolerated after single and multiple oral administration up to the highest doses. PRI‐002 was absorbed rapidly and drug exposure increased proportional to dose. During repeated daily administration, the drug accumulated by a factor of about three. Steady‐state conditions were reached after 1 to 2 weeks. Conclusions: The safety and PK results encourage further clinical development of PRI‐002.

4 October 2010 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
AMAndreas Müller‐Schiffmann
Andreas Müller‐Schiffmann
JMJulia März‐Berberich
Julia März‐Berberich
AAAksana Andreyeva
Aksana Andreyeva
RRRaik Rönicke
Raik Rönicke
DBDirk Bartnik
Dirk Bartnik
CKCarsten Korth
Carsten Korth

17 September 2015 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
LLLeonie H. E. Leithold
Leonie H. E. Leithold
NJNan Jiang
Nan Jiang
JPJulia Post
Julia Post
TZTamar Ziehm
Tamar Ziehm
ESElena Schartmann
Elena Schartmann
DWDieter Willbold
Dieter Willbold